Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Management of relapse after allo-SCT for AML and the role of second transplantation

Bone Marrow Transplantation volume 44, pages 769–777 (2009)Cite this article

Abstract

Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2–20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Craddock CF . Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant 2008; 41: 415–423.

    Article  CAS  PubMed  Google Scholar 

  2. Meijer E, Cornelissen JJ . Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. Semin Oncol 2008; 35: 449–457.

    Article  CAS  PubMed  Google Scholar 

  3. Barrett AJ, Savani BN . Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661–1672.

    Article  CAS  PubMed  Google Scholar 

  4. Giralt SA, Champlin RE . Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994; 84: 3603–3612.

    CAS  PubMed  Google Scholar 

  5. Barrett AJ, Savani BN . Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008; 45: 49–59.

    Article  CAS  PubMed  Google Scholar 

  6. Dombret H, Raffoux E, Gardin C . Acute myeloid leukemia in the elderly. Semin Oncol 2008; 35: 430–438.

    Article  PubMed  Google Scholar 

  7. Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ . Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1160–1168.

    Article  PubMed  Google Scholar 

  8. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 1027–1032.

    Article  CAS  PubMed  Google Scholar 

  9. Kobayashi K, Kami M, Murashige N, Kusumi E, Kishi Y, Hamaki T et al. Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. Br J Haematol 2005; 129: 795–802.

    Article  PubMed  Google Scholar 

  10. Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003; 9: 706–713.

    Article  PubMed  Google Scholar 

  11. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721–727.

    Article  CAS  PubMed  Google Scholar 

  12. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005; 36: 157–162.

    Article  CAS  PubMed  Google Scholar 

  13. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675–3684.

    Article  CAS  PubMed  Google Scholar 

  14. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK . Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007; 13: 116–123.

    Article  PubMed  Google Scholar 

  15. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: 709–719.

    Article  CAS  PubMed  Google Scholar 

  16. Singhal S, Powles R, Treleaven J, Mehta J . Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b. Bone Marrow Transplant 1997; 19: 1151–1153.

    Article  CAS  PubMed  Google Scholar 

  17. Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269–275.

    CAS  PubMed  Google Scholar 

  18. Kishi K, Takahashi S, Gondo H, Shiobara S, Kanamaru A, Kato S et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461–466.

    Article  CAS  PubMed  Google Scholar 

  19. Ravandi F, Kantarjian H, Cohen A, Davis M, O’Brien S, Anderlini P et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 2001; 27: 1221–1225.

    Article  CAS  PubMed  Google Scholar 

  20. Michallet M, Tanguy ML, Socie G, Thiébaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108: 400–407.

    Article  CAS  PubMed  Google Scholar 

  21. Wagner JE, Vogelsang GB, Zehnbauer BA, Griffin CA, Shah N, Santos GW et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 1992; 9: 205–209.

    CAS  PubMed  Google Scholar 

  22. Russell JA, Bowen T, Brown C, Luider J, Ruether JD, Stewart D et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplant 1996; 18: 501–505.

    CAS  PubMed  Google Scholar 

  23. Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304–313.

    Article  CAS  PubMed  Google Scholar 

  24. Munoz A, Badell I, Olive T, Verdeguer A, Gómez P, Bureo E, Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). Haematologica 2002; 87: 331–332.

    PubMed  Google Scholar 

  25. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydło R, Zwaan FE et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991; 79: 567–574.

    Article  CAS  PubMed  Google Scholar 

  26. Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008; 42: 783–789.

    Article  CAS  PubMed  Google Scholar 

  27. Kedmi M, Resnick IB, Dray L, Aker M, Samuel S, Gesundheit B et al. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 2009; 15: 483–489.

    Article  CAS  PubMed  Google Scholar 

  28. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21: 2540–2544.

    Article  CAS  PubMed  Google Scholar 

  29. Bethge WA, Storer BE, Maris MB, Flowers ME, Maloney DG, Chauncey TR et al. Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. Exp Hematol 2003; 31: 974–980.

    Article  PubMed  Google Scholar 

  30. Feinstein LC, Sandmaier BM, Maloney DG, Maris MB, Gooley TA, Chauncey TR et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003; 9: 266–272.

    Article  PubMed  Google Scholar 

  31. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR . Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272–279.

    Article  CAS  PubMed  Google Scholar 

  32. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/− Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115: 622–629.

    Article  CAS  PubMed  Google Scholar 

  33. Yavuz S, Paydas S, Disel U, Sahin B . IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther 2006; 13: 389–393.

    Article  PubMed  Google Scholar 

  34. Mielke S, Barrett AJ . Management of relapse and minimal residual disease after stem cell transplantation. In: Treleaven J, Barrett AJ (eds). Hematopoietic Stem Cell Transplantation in Clinical Practice. Churchill Livingstone Elsevier: London; New York, 2009, 409–416.

    Chapter  Google Scholar 

  35. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  PubMed  Google Scholar 

  36. Lee JH, Lee KH, Kim S, Seol M, Kim SH, Kim WK et al. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leuk Res 2001; 25: 305–312.

    Article  CAS  PubMed  Google Scholar 

  37. Schmid C, Schleuning M, Aschan J, Ringdén O, Hahn J, Holler E et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004; 18: 1430–1433.

    Article  CAS  PubMed  Google Scholar 

  38. Al-Qurashi F, Ayas M, Al Sharif F, Ibrahim E, Sahovic E, Al Mahr M et al. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology 2004; 9: 123–129.

    Article  CAS  PubMed  Google Scholar 

  39. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842–2848.

    CAS  PubMed  Google Scholar 

  40. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  41. Carlens S, Remberger M, Aschan J, Ringden O . The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 2001; 7: 31–38.

    Article  CAS  PubMed  Google Scholar 

  42. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405–412.

    Article  CAS  PubMed  Google Scholar 

  43. Loren AW, Porter DL . Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483–493.

    Article  CAS  PubMed  Google Scholar 

  44. Luznik L, Fuchs EJ . Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9: 123–137.

    Article  PubMed  Google Scholar 

  45. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  46. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110: 2761–2763.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107: 1325–1331.

    Article  CAS  PubMed  Google Scholar 

  48. Choi SJ, Lee JH, Lee JH, Kim S, Seol M, Lee YS et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004; 18: 1789–1797.

    Article  CAS  PubMed  Google Scholar 

  49. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Mehta J . Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma 1999; 32: 505–512.

    Article  CAS  PubMed  Google Scholar 

  50. Berthou C, Leglise MC, Herry A, Balcon D, Hardy E, Lessard M et al. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998; 12: 1676–1681.

    Article  CAS  PubMed  Google Scholar 

  51. Cunningham I . Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma 2006; 47: 1754–1767.

    Article  PubMed  Google Scholar 

  52. Chong G, Byrnes G, Szer J, Grigg A . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000; 26: 1011–1015.

    Article  CAS  PubMed  Google Scholar 

  53. van Rhee F, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055–1061.

    Article  CAS  PubMed  Google Scholar 

  54. Porter DL, Collins Jr RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214–1221.

    CAS  PubMed  Google Scholar 

  55. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 607–612.

    Article  CAS  PubMed  Google Scholar 

  56. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A . Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol 2007; 4: 491–495.

    Article  CAS  PubMed  Google Scholar 

  57. Tamai H, Shioi Y, Yamaguchi H, Okabe M, Wakita S, Mizuki T et al. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion. Leukemia 2008; 22: 1273–1274.

    Article  CAS  PubMed  Google Scholar 

  58. Specchia G, Pastore D, Carluccio P, Spinosa G, Giannoccaro M, Rizzi R et al. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 2007; 86: 425–428.

    Article  CAS  PubMed  Google Scholar 

  59. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G . Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007; 31: 257–259.

    Article  CAS  PubMed  Google Scholar 

  60. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002; 169: 4253–4261.

    Article  CAS  PubMed  Google Scholar 

  61. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S . Clofarabine: past, present, and future. Leuk Lymphoma 2007; 48: 1922–1930.

    Article  CAS  PubMed  Google Scholar 

  62. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45–51.

    Article  CAS  PubMed  Google Scholar 

  63. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762–1769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Robak T, Lech-Maranda E, Korycka A, Robak E . Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006; 13: 3165–3189.

    Article  CAS  PubMed  Google Scholar 

  65. Messori A, Bosi A, Bacci S, Laszlo D, Trippoli S, Locatelli F et al. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant 1999; 23: 489–495.

    Article  CAS  PubMed  Google Scholar 

  66. Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008; 14: 197–207.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938–4945.

    Article  CAS  PubMed  Google Scholar 

  68. Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769–774.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center, Nashville, TN, USA

    B N Savani, N Reddy, S Goodman & M Jagasia

  2. Division of Hematology and Oncology, Department of Internal Medicine II, Allogeneic Stem Cell Transplant Center, Julius Maximilian University, Würzburg, Germany

    S Mielke

  3. Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK

    K Rezvani

Authors
  1. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Mielke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Jagasia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Rezvani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B N Savani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savani, B., Mielke, S., Reddy, N. et al. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 44, 769–777 (2009). https://doi.org/10.1038/bmt.2009.300

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.300

Keywords

This article is cited by

Search

Advanced search

Quick links